Boris Reznik

During his career spanning four decades, Dr. Reznik founded and built technology companies into market leaders, managed multiple INC. 500 companies, and led multiple programs that achieved NDA and BLA approvals. He has been an investor and/or principle in multiple technology-based companies that achieved valuations in public or private markets ranging from millions to billions. Dr. Reznik holds a number of patents.

He has authored numerous publications. Dr. Reznik earned an A.S. in Mathematics and an M.S. in Mechanical Engineering from different universities and a Ph.D. from the Soviet Academy of Sciences.

Previous Affiliations:

1. Biorasi
2. Venvalo Group

Thomas Ichim

Dr. Ichim is a seasoned biotechnology entrepreneur who dedicated over 20 years to launching, growing, and realizing value of multiple biotech companies. Dr. Ichim is especially renowned for his advances in regenerative medicine and immunotherapy. He has been a Manager, Vice President, as well as President and CEO of emerging biotechnology startups and billion-dollar public enterprises. Dr. Ichim holds a Ph.D. in Immunology and has published over 130 peer-reviewed articles and authored 3 textbooks.Dr.

Ichim is an inventor of over 360 patents and patent applications. Dr. Ichim communicates through his highly popular Twitter account (@exosome). He earned his BSc in Biology from the University of Waterloo. MSc in Microbiology and Immunology from the University of Western Ontario. Ph.D. in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

Previous Affiliations:

1. Biorasi
2. Fibrobiologics

Vladyslav Bykoriz

Pharmaceutical industry executive with broad hands-on leadership experience in all areas of Medical Affairs including risk management, pharmacovigilance, R&D, regulatory affairs, and other areas. Dr. Bykoriz management and executive medical affairs positions with Zenaka, Boehringer Ingelheim, Abbot and the last 19 years at Pfizer. He served on Pfizer Medical Policy Group, Pfizer Cardiovascular Safety Council, and Pfizer Innovation Council. Vlad obtained his MS and MD degrees from Kiev Medical University and his PhD from Kiev Institute of Cardiology.

Previous Affiliations:

1. Pfizer
2. Abbot

Armin Rath

Senior executive with 10+ years of leadership in both private and public life sciences companies, combining scientific, commercial, and management expertise. Experienced across therapeutic areas in drugs and medical devices, with strong knowledge of U.S. and European drug markets. Skilled in team leadership, international collaboration, and deal negotiation. Dr. Rath held various executive leadership positions like Head of Product Development at Naya Biosciences, Head of Business Development & Alliance Management at Cytovia Therapeutics, CEO/Managing Director Shionogi Germany/Spain, Business Unit Director at Baxter, and Head of Pricing at Pharmacia. Dr. Rath held full P&L responsibility and has led M&A deals exceeding $50M, including securing $20M+ in investments.

Previous Affiliations:

1. NAYA Biosciences
2. Pfizer

Russel Kaufman

Dr. Russel Kaufman is a venture partner at Pappas Capital, as well as President Emeritus of The Wistar Institute. Prior to Wistar, Dr. Kaufman was associated with Duke University, for over 25 years, with multiple professional and administrative appointments, including Professor of Medicine, Chief, Division of Medical Oncology and Transplantation, Dean of School of Medicine, among others. He is considered a Key Opinion Leader in the areas of Translational Oncology, Stem Cells, and Genomics. Dr. Kaufman earned a BS and MD from the Ohio State University.

Previous Affiliations:

1. Pappas Capital
2. The Wistar Institute